1World Health Organization.WHO Cancer Mortality Database [EB/0L].2014.http://www-depdb.iarc.fr/who/menu.htm.
2LOUWMAN W J,VULTO J C M,VERHOEVEN R H A,et al.Clinical epidemiology of breast cancer in the elderly [J].Eur J Cancer,2007,43(15):2242-2252.
3SAMI G D,RICHARD M E,GARY M C.Tumor characteristics and clinical outcome of elderly women with breast cancer [J].J Natl Cancer Inst,2000,92(7):550-556.
4DOWNEY L B.Adjuvant treatment of breast cancer in the elderly.Understanding and addressing the challenges [J].Oncology(Willistion Park),2008,22(3):286-293.
5ZAPKA J G,STODDARD A M,COSTANZA M E,et al.Breast cancer screening by mammography:utilization and associated factors [J].Am J Public Health,1989,79(11):1499-1502.
6VAN DE W W,MARKOPOULOS C,VAN DE V C J,et al.Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer [J].JAMA,2012,307(6):590-597.
7MUSS H B,BERRY D A,CIRRINCIONE C,et al.Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer:the Cancer and Leukemia Group B Experience [J].J Clin Oncol,2007,25(24):3699-3704.
8FARGEOT P,BONNETERRE J,ROCHE H,et al.Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable,node-positive,elderly breast cancer patients:6-years follow-up results of the French Adjuvant Study Group 08 trial [J].J Clin Oncol,2004,22(23):4622-4630.
9MUSS H B,BERRY D A,CIRRINCIONE C T,et al.Adjuvant chemotherapy in older women with early-stage breast cancer [J].N Engl J Med,2009,360(20):2055-2065.
10GIANNI L,HERMAN E H,LIPSHULTZ S E,et al.Anthracycline cardiotoxicity:from bench to bedside [J].J Clin Oncol,2008,26(22):3777-3784.
